SCHEMBL5248481

SCHEMBL5248481

CN1N=C2CCN(C(=O)[C@@H](COCc3ccccc3)NC(=O)C(C)(C)NC(=O)OC(C)(C)C)C[C@@]2(Cc2ccccc2)C1=O

nearest known ligand 0.79

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 6/20 0.79
PPARA Q07869 2/20 0.41
CTSS P25774 1/20 0.39
PPARG P37231 1/20 0.38
UGCG Q16739 7/20 0.37
KLK7 P49862 2/20 0.36
KLK5 Q9Y337 2/20 0.36
CYP3A4 P08684 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5253549 1.00 GHSR (0.79) GHSRPPARACTSSPPARGUGCG
SCHEMBL5248471 1.00 GHSR (0.79) GHSRPPARACTSSPPARGUGCG
SCHEMBL5254134 0.96 GHSR (0.73) GHSRPPARACTSSPPARGUGCG
SCHEMBL5254137 0.96 GHSR (0.73) GHSRPPARACTSSPPARGUGCG
SCHEMBL5254132 0.96 GHSR (0.73) GHSRPPARACTSSPPARGUGCG
SCHEMBL7134095 0.93 GHSR (0.83) GHSRUGCGCYP3A4
SCHEMBL7134090 0.93 GHSR (0.83) GHSRUGCGCYP3A4
SCHEMBL31163744 0.93 GHSR (0.80) GHSRPPARACTSSPPARGUGCG
SCHEMBL5251055 0.93 GHSR (0.68) GHSRPPARACTSSUGCGKLK7
SCHEMBL5251049 0.93 GHSR (0.68) GHSRPPARACTSSUGCGKLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1031575-B1 Process for preparing growth hormone secretagogues PFIZER PROD INC (US) 2004-09-29 EP claimed
US-6673929-B2 Process for preparing growth hormone secretagogues PFIZER INC. 2004-01-06 US claimed
US-20030158414-A1 Process for preparing growth hormone secretagogues RAQUALIA PHARMA INC. (JP) 2003-08-21 US claimed
US-20020002283-A1 Process for preparing growth hormone secretagogues RAQUALIA PHARMA INC. (JP) 2002-01-03 US claimed
EP-1031575-A1 Process for preparing growth hormone secretagogues Pfizer Products Inc. (US) 2000-08-30 EP claimed
EP-0869968-B1 GROWTH-HORMONE SECRETAGOGUES PFIZER (US) 2007-05-02 EP disclosed
EP-1000085-B1 TREATMENT OF INSULIN RESISTANCE WITH GROWTH HORMONE SECRETAGOGUES PFIZER PROD INC (US) 2005-09-28 EP disclosed
US-6867202-B1 Increasing level of endogenous growth hormone using growth hormone secretagogue such as 2-amino-N-(2-(3a-benzyl-2-methy-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-(4,3 -c)pyridin-5-yl)-1-benzyloxymethyl-2-oxo-ethyl)-isobutyramide tartarate salt PFIZER INC. (US) 2005-03-15 US disclosed
EP-1031575-B1 Process for preparing growth hormone secretagogues PFIZER PROD INC (US) 2004-09-29 EP disclosed
EP-1449842-A1 Process for the preparation of pyrazolopyridine tartrates Pfizer Products Inc. (US) 2004-08-25 EP disclosed
US-6673929-B2 Process for preparing growth hormone secretagogues PFIZER INC. 2004-01-06 US disclosed
US-6657063-B1 (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino) ethoxy)phenyl)acetic acid derivatives; dietetics; hypotensive agents; non-insulin dependent diabetes treatment PFIZER INC. 2003-12-02 US disclosed
US-20020002283-A1 Process for preparing growth hormone secretagogues RAQUALIA PHARMA INC. (JP) 2002-01-03 US disclosed
US-6313140-B1 ADMINISTERING TO A HUMAN OR OTHER ANIMAL PYRAZOLOPYRIMIDINE DERIVATIVE FOR PROPHYLAXIS OR THERAPY OF DISEASE OR CONDITION WHICH MAY BE TREATED OR PREVENTED BY GROWTH HORMONE PFIZER INC. 2001-11-06 US disclosed
US-6306875-B1 ADMINISTERING GROWTH HORMONES DIPEPTIDE COMPOUNDS WHICH ARE GROWTH HORMONE SECRETAGOGUES AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS. PFIZER INC. 2001-10-23 US disclosed
US-6278000-B1 INCREASE LEVEL OF ENDOGENOUS GROWTH HORMONE; USEFUL IN THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING AND OBESITY, ACCELERATING BONE FRACTURE REPAIR PFIZER INC. 2001-08-21 US disclosed
US-6124264-A GROWTH HORMONE SECRETAGOGUE IN A HUMAN OR OTHER ANIMAL TO TREAT OSTEOPOROSIS, CONGESTIVE HEART FAILURE, AGING, OBESITY; BONE AND WOUND HEALING AGENTS PFIZER INC. (US) 2000-09-26 US disclosed
EP-1031575-A1 Process for preparing growth hormone secretagogues Pfizer Products Inc. (US) 2000-08-30 EP disclosed
US-6110932-A INCREASE THE LEVEL OF ENDOGENOUS GROWTH HORMONE FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ACCELERATING WOUND HEALING PFIZER INC. (US) 2000-08-29 US disclosed
US-6107306-A OSTEOPOROSIS PFIZER INC. (US) 2000-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002283-A1 Process for preparing growth hormone secretagogues GHRHR, GHSR, PRLHR GHSR 2/4885PPARA 3080/4885CTSS 1860/4885
US-20030158414-A1 Process for preparing growth hormone secretagogues GHRHR, GHSR, PRLHR GHSR 2/4885PPARA 3080/4885CTSS 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.